Compare LUNG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | CVM |
|---|---|---|
| Founded | 1995 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 53.1M |
| IPO Year | 2020 | 1987 |
| Metric | LUNG | CVM |
|---|---|---|
| Price | $2.54 | $6.33 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.81 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 58.9K |
| Earning Date | 11-12-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $91,664,000.00 | N/A |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.59 | N/A |
| 52 Week Low | $1.31 | $1.98 |
| 52 Week High | $9.37 | $32.70 |
| Indicator | LUNG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 42.89 |
| Support Level | $1.96 | $6.20 |
| Resistance Level | $1.74 | $6.69 |
| Average True Range (ATR) | 0.20 | 0.54 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 91.13 | 35.71 |
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.